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ABSTRACT
Hematopoietic stem cells (HSC), including umbilical cord blood CD34+ stem cells 
(UCB-CD34+), are used for the treatment of several diseases. Although different 
studies suggest that bone marrow mesenchymal stem cells (BM-MSC) support 
hematopoiesis, the exact mechanism remains unclear. Recently, extracellular vesicles 
(EVs) have been described as a novel avenue of cell communication, which may 
mediate BM-MSC effect on HSC. In this work, we studied the interaction between 
UCB-CD34+ cells and BM-MSC derived EVs. First, by sequencing EV derived miRNAs 
and piRNAs we found that EVs contain RNAs able to influence UCB-CD34+ cell fate. 
Accordingly, a gene expression profile of UCB-CD34+ cells treated with EVs, identified 
about 100 down-regulated genes among those targeted by EV-derived miRNAs and 
piRNAs (e.g. miR-27b/MPL, miR-21/ANXA1, miR-181/EGR2), indicating that EV 
content was able to modify gene expression profile of receiving cells. Moreover, we 
demonstrated that UCB-CD34+ cells, exposed to EVs, significantly changed different 
biological functions, becoming more viable and less differentiated. UCB-CD34+ gene 
expression profile also identified 103 up-regulated genes, most of them codifying 
for chemokines, cytokines and their receptors, involved in chemotaxis of different 
BM cells, an essential function of hematopoietic reconstitution. Finally, the exposure 
of UCB-CD34+ cells to EVs caused an increased expression CXCR4, paralleled by an 
in vivo augmented migration from peripheral blood to BM niche in NSG mice. This 
study demonstrates the existence of a powerful cross talk between BM-MSC and 
UCB-CD34+ cells, mediated by EVs, providing new insight in the biology of cord blood 
transplantation.
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INTRODUCTION
Umbilical cord blood CD34+ stem cells (UCB-CD34+) 
are a source of hematopoietic stem cells (HSC) used for the 
treatment of numerous diseases. Since HSC fate is bound 
to different factors, like bone marrow microenvironment, 
the communication between different cell types becomes 
an important mechanism of stemness maintenance and 
of differentiation [1]. In this scenario, cells communicate 
by growth factors, cytokines, adhesion molecules and 
extracellular vesicles (EVs) [2–4].
EVs are cell derived vesicles surrounded by a lipid 
bilayer, ranging from 30 nm to 2.000 nm in diameter 
depending on their origin [5]. EVs can be divided 
in three main classes: exosomes, microvecicles and 
apoptotic bodies, which are different in terms of size 
and mechanism of generation. [4–8]. EVs are enriched 
in phosphatidylserine, especially the budding ones, 
cytoplasmic protein, mRNA, miRNA and DNA [6, 9–11]. 
They mediate intercellular communication, interacting 
with target cells by controlling fundamental biological 
functions [4, 12, 13]. EVs have been isolated from 
different body fluids [14] and they have an important role 
not only in regulation of normal physiological processes 
[15] but also in several diseases [16–18]. Literature’s 
data show that EVs are involved in tumor invasion, 
inflammation, blood clotting and, last but not least, 
regulation of stem cells [6, 19].
The maintenance of self-renewal, differentiation 
and aging of HSC can be influenced by bone marrow 
microenvironment [20, 21]. Since all the above-mentioned 
processes are strictly dependent and regulated by cellular 
communication, we studied the communication mediated 
by EVs. 
Bone marrow mesenchymal stem cells (BM-MSC) 
are a component of hematopoietic microenvironment [22] 
and support hematopoiesis by the constitutive ability to 
secrete soluble factors as SCF, LIF, IL6 [23–25]. MSC are 
fibroblast-like multipotent cells present in different tissues, 
with the ability to differentiate into specialized cells like 
adipocytes, chondrocytes, osteoblasts, myocytes and neurons 
[26, 27]. In addition to their stem cell properties, MSC 
have been shown to possess immunoregolatory abilities 
influencing both adaptive and innate immune responses. 
Due to their ability, MSC and their derived EVs have a 
therapeutic effect in regenerative medicine [26–30], tumor 
growth/inhibition [31] and immunoregulation [13, 32].
On this basis, we isolated EVs from BM-MSC and 
characterized their small RNA cargo, that includes miRNA 
and piRNA. We found that BM-MSC-EVs influence 
UCB-CD34+ cell gene expression pattern, inducing cell 
survival, inhibiting cell differentiation and promoting their 
migration towards bone marrow.
Our findings, suggesting that BM-MSC-EVs could 
influence the UCB+CD34+ fate, may be helpful for their 
transplantation use.
RESULTS
Characterization of BM-MSC derived EVs
To characterize isolated BM-MSC, we checked the 
expression profile of MSC specific surface markers such as 
CD29, CD90, CD73, CD105, CD49d, CD146 and CD44. 
Cytometric analysis from three different experiments 
showed that cells were positive for CD29 (one representative 
experiment = 100%), CD90 (100%), CD73 (94%), CD105 
(70%), CD49d (24%), CD146 (71%) and CD44 (97%) 
(Figure 1A). To confirm the purity of isolated BM-MSC, we 
also analyzed hematopoietic surface markers like HLA-DR, 
CD45, CD14 and endothelial marker like CD31 and 
CD144. In both cases they were negative (Figure 1A). EVs, 
isolated from BM-MSC, were detected by transmission 
electron microscopy showing spheroid morphology 
and a size lower than 2 µm (Figure 1B); moreover, flow 
cytometry analysis confirmed their size range between 
100 nm and 2 µm (Figure 1C). EVs were positive, in two 
different experiments, for BM-MSC markers like CD29 
(one representative experiment = 61%), CD90 (72%), CD73 
(63%), CD105 (35%), CD146 (32%), CD44 (70%) and for 
exosome marker CD81 (40%); they were negative, instead, 
for hematopoietic marker CD45, proving their MSC cellular 
origin (Figure 1D). 
Identification of miRNA and piRNA expression 
signature in BM-MSC-EVs
A Bioanalyzer profile of total EVs RNAs revealed 
no peaks of ribosomal RNAs, 18S and 28S, and a 
characteristic peak of small RNAs below 200 bases in 
respect to origin cells (Figure 2A and 2B). Small-RNA 
analysis, conducted by a small-RNA chip assay, showed 
an enrichment of small-RNAs that fell within the range of 
17–100 nucleotides (Figure 2C).
To characterize the miRNA and piRNA content 
in BM-MSC-EVs, we analyzed, by next generation 
sequencing, all small RNAs present in EVs. We obtained, 
after filtering out low quality reads and trimming the 
adaptor, about 1.5 million of reads. To identify the 
small-RNA distribution biotypes, we mapped all RNA 
reads to known RNA sequences and we found 3.3% of 
miRNAs and 0.6% of piRNAs sequences (Figure 2D). 
From sequencing of data we identified 87 miRNAs 
by iMir tool [33], and 5 piRNAs with their clusters by 
piPipes tool [34] and piRNABank [35] (Figure 2E and 2F, 
Supplementary Material, Table S1). 
BM-MSC-EVs miRNA and piRNA sequencing 
and correlation with down-regulated genes in 
UCB-CD34+ cells treated with BM-MSC-EVs
To define the changes due to BM-MSC-EVs 
miRNAs and piRNAs on gene expression patterns of 
UCB-CD34+ cells, we performed a gene expression profile 
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comparing UCB-CD34+ cells treated with EVs versus 
not treated detecting 103 up-regulated and 100 down-
regulated genes (with p-value < 0.05 and logFC = –0.7) 
(Figure 3A and Supplementary Material, Table S2). 
Interestingly, analyzing together the sequencing of EVs 
and gene expression data of UCB-CD34+ cells treated with 
EVs, by Ingenuity Pathways Analysis software, we identify 
at least one down-regulated target gene for each EVs 
miRNA (e.g., miR-3168/LYZ, miR-27b-3p/ZFP36, miR21-
5p/ANXA1) (Table 1). To validate this correlation, we 
transfected five EVs miRNAs (miR-27b-3p, miR-10a-5p, 
miR-21-5p, miR-181a-5p and miR92a-3p) in UCB-CD34+ 
cells (Figure 3B) confirming the down-regulation of their 
predicted target genes (miR-27b-3p/MPL and ZFP36, 
Figure 1: Immunophenotypic characterization of the BM-MSC and derived EVs. (A) FITC, APC, PerCp and PE-conjugated 
antibodies were used for phenotyping the primary BM-MSC by flow cytometry. Cells were positive for CD29 (100%), CD90 (100%), 
CD73 (94%), CD105 (70%), CD49d (24%), CD146 (71%) and CD44 (97%) and negative for CD45, HLA-DR, CD14, CD144, CD31. 
One of three representative experiments is shown. (B) Two TEM representative images of EVs derived from BM-MSC are shown. EVs 
appear round and with heterogeneous size under 2 µm. (C) Representative FACS analysis of: 0,3 – 0,9 – 3 μm beads used as internal 
size standards, filtered PBS used like a negative control and BM-MSC-EVs. (D) Representative flow cytometric dot plots on BM-MSC 
derived vesicles showing positive BM-MSC markers (CD29, CD90, CD73, CD105, CD49d, CD146 and CD44), exosomes marker CD81 
and negative hematopoietic marker CD45. Dot lines indicate the isotypic controls. The Kolmogrov-Smirnov statistical analyses between 
relevant antibodies and the isotypic control was significant (P < 0.001). 
Oncotarget6679www.impactjournals.com/oncotarget
miR-10a-5p/MPL, miR-21-5p/ANXA1, miR-181a-5p/CEBPA 
and EGR2, miR92a-3p/ CEBPA and EGR2) (Figure 3C).
Along with miRNAs, recent studies indicated that 
also piRNAs play a role, not only in transposon silencing, 
but also in epigenetic and in post-transcriptional regulation 
of gene expression [36, 37]. Based on this evidence, we 
postulate that piRNAs presence could influence mRNAs 
expression in UCB-CD34+ treated with EVs. To identify 
the target mRNAs of our piRNAs, we used miRanda 
matching each piRNA sequence with 5′-UTRs, CDSs or 
3′-UTRs regions of all known human RNAs databases. 
Surprisingly, we found from the down-regulated genes of 
our profile only 4 putative mRNA target sequences of two 
piRNAs (hsa_piR_020814_DQ598650, hsa_piR_002732_
DQ573682) (Table 2). To identify the target mRNAs 
for the other 3 piRNAs (hsa_piR_004307_DQ575881, 
hsa_piR_017723_DQ594464, hsa_piR_016745_DQ593052) 
on our gene expression analysis, we modified the logFC form 
−0.7 to −0.4 detecting a wider list of about 400 down-regulated 
genes. Subsequently, analyzing together all piRNA target 
sequences and the down-regulated genes, by IPA, we identify 
18 piRNA target genes (Supplementary Material, Table S3). 
Figure 2: Bioanalyzer profile and small RNA sequencing of BM-MSC derived EVs. Representative bioanalyzer profile of 
the RNAs contained in BM-MSC (A) and in BM-MSC-EVs (B). The electropherograms show the size distribution in nucleotides (nt) and 
fluorescence intensity (FU) of total RNA. The short peak at 25 nt is an internal standard. In BM-MSC the most dominant peaks are the 
18S and 28S ribosomal RNA, whereas in EVs is the small RNAs peak respect to the absent rRNA peaks. (C) Representative bioanalyzer 
profile of small RNAs performed on EVs derived from BM-MSC showing an enrichment of small RNAs of the size of miRNAs in respect 
to the cells of origin. Three different samples of cells and EVs were analyzed. (D) Pie-charts showing the percentage of small RNA species 
identified in BM-MSC-EVs by small RNA sequencing. (E) Mature miRNA list obtained by sequencing BM-MSC-EVs small RNA content. 
The 87 microRNAs, obtained by miRanalyzer, were subdivided in quartiles on the base of readCount numbers and the most representative 
(1st quartile) were used in the integrated analysis with gene expression profile. (F) piRNA list obtained by sequencing BM-MSC-EVs small 
RNA content with readCount more than five.
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These data indicate that the EVs miRNAs and piRNAs are 
able to modify gene expression profile of receiving cells.
EVs treatment induces cell survival and inhibits 
apoptosis of UCB-CD34+ cells
To characterize cell biological processes modulated 
by EVs miRNAs, we analyzed miRNA-targeted genes 
in UCB-CD34+ cells by gene expression profile. Gene 
ontology analysis revealed that all genes were involved 
in different down-regulated functions as cell death, 
growth and proliferation, movement and development 
(Table 3). Cell death was the first and the most 
down-regulated function (p = 3.89−10) identified from 
the analysis, including about 35 miRNA-targeted genes 
from the profile (Table 4). To validate gene expression 
analysis, we confirmed, by real Time PCR, the down-
regulation of some genes like ANXA1, CEBPA and EGR2 
(p-value < 0.001) respect to the control (Figure 4A). Of 
interest, similarly to miRNA also piRNA-targeted genes 
from our profile (with p-value < 0.05 and logFC = −0.4) 
resulted to be involved in the previous listed down-
regulated function as cell death (Supplementary Material, 
Table S4).
Moreover, we demonstrated that BM-MSC EVs are able 
to significantly inhibit apoptotic pathways (p-value < 0.05) 
(Figure 4B and 4C) and caspase 3/7 activity (p-value < 0.05) 
(Figure 4D) in UCB-CD34+ cells compared to the control.
No difference, instead, was found between 
UCB-CD34+ cells cultured in conditioned BM-MSC 
medium deprived of EVs or in medium alone (data not 
shown), indicating that BM-MSC-EVs carried specific 
miRNAs to make cells more viable.
To further confirm apoptosis process reduction 
due to BM-MSC-derived EVs miRNAs, we transfected 
together miR-21-5p, miR-181a-5p and miR92a-3p 
Figure 3: Gene expression profile of UCB treated with BM-MSC-EVs vs control and correlation with EVs miRNAs. 
(A) Scatter plot of average gene expression levels between UCB-CD34+ treated with EVs and UCB-CD34+ control. Red and green dots 
represent up-regulated and down-regulated genes, respectively. Differential score was set at ±30 (p < 0.001) with log2fold difference ≤ –0.7 
or ≥ 0.7 (more than 1.5-fold change). A list composed by 130 up-regulated and 100 down-regulated genes was used for further analysis. 
Yellow dots represent genes with a significant differential score (± 30; p < 0.001) but with a log2fold difference lower than 0.7 or upped 
than –0.7, and subsequently excluded for further analysis. With arrows are indicated the most representative genes in the Gene Ontology 
analysis with IPA software. (B) miR-27b-3p, miR-10a-5p, miR-21-5p, miR-181a-5p and miR92a-3p relative expression was determined by 
qRT-PCR in UCB-CD34+ transfected with 60 nM of miRNAs mimic (miR-27b-3p, miR-10a-5p, miR-21-5p, miR-181a-5p and miR92a-3p) 
and their scramble. Each data samples were normalized to the endogenous reference RNU44 by use of the E-ΔΔCp. (C) MPL, EGR2, CEBPA, 
and ANXA mRNA relative expression was determined by qRT-PCR in UCB-CD34+ transfected with 60 nM of miRNAs mimic (miR-27b-3p, 
miR-10a-5p, miR-21-5p, miR-181a-5p and miR92a-3p) and their scramble. Each data samples were normalized to the endogenous reference 
GAPDH by use of the E-ΔΔCp. The bar-graphs represented mean + SD from three independent experiments. Statistically significant analyses 
are indicated by asterisks: *p < 0.05, **p < 0.01 and ***p < 0.001.
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(Figure 4E) in UCB-CD34+. After transfection we found 
ANXA1, CEBPA and EGR2, significantly down-regulated 
(ANXA1 p-value < 0.05 and EGR2 p-value < 0.001) 
(Figure 4F) in transfected UCB-CD34+ cells vs control. 
Furthermore, the same cells showed a significant decrease 
of apoptosis pathway (p-value < 0.05) (Figure 4G and 4H) 
and of caspase 3/7 activity (p-value < 0.05) (Figure 4I). 
EVs treatment induces a decrease of 
differentiation of UCB-CD34+ cells
EVs miRNAs induce a decrease of UCB-CD34+ 
cells differentiation. Analyzing the 16 genes identified 
in this class of function from the gene expression profile, 
we observed a decrease of RNAs involved in cellular 
maturation to all hematopoietic lineages (Table 5). To 
validate the down-regulation of these genes, we assessed 
the transcript levels of some of them like MPL and ZFP36. 
As expected, both genes were significantly down-regulated 
(MPL p-value < 0.001 and ZFP36 p-value = 0.02) 
in UCB-CD34+ cells treated with EVs respect to the 
control (Figure 5A).
A reduction of cell differentiation is also one of 
the most down-regulated function found by the analysis 
of piRNA down-regulated target genes (Supplementary 
Material, Table S4) supporting the idea that EVs miRNAs 
and piRNAs regulate the same functions in UCB-CD34+ 
cells.
Moreover, a decrease of cellular maturation 
was confirmed by FACS analysis, evaluating different 
hematological markers (CD19+, CD33+ and CD38+). 
The expression of CD19+, CD33+ and CD38+ resulted 
to be significantly lower in UCB-CD34+ cells treated 
with EVs when compared to control (CD19+ and 
Table 1: Correlation of the most representative (1st quartile) sequenced EVs miRNAs and 
down-regulated target genes in UCB-CD34+ treated with BM-MSC-EVs
miRNA Regulated genes
Name readCount Symbol (Entrez Gene ID)
hsa-miR-3168 14423 AGPAT9 (84803), COL24A1 (255631), LYZ (4069)
hsa-miR-22-3p 2447 AGPAT9 (84803), CSF1R (1436), EMP1 (2012), FCER2 (2208), GPNMB (10457), KBTBD11 (9920), RGS2 (5997)
hsa-miR-378a-3p 775 FGR (2268), GPNMB (10457), ZFP36L2 (678)
hsa-miR-205-5p 523 CAT (847), CYBB (1536), LHFPL2 (10184)
hsa-miR-27b-3p 458 CYP1B1 (1545), FOSB (2354), GLRX (2745), HOXA5 (3202), KBTBD11 (9920), MPL (4352), MTURN (222166), ZFP36 (7538), ZFP36L2 (678)
hsa-miR-423-5p 347 ALDH1A2 (8854), C19orf59 (199675), CLDN23 (137075), CLEC5A (23601), FOSB (2354), MTURN (222166), ZFP36 (7538)
hsa-miR-21-5p 272 ANXA1 (301), OLR1 (4973), S100A10 (6281), TBC1D2 (55357), TGFBI (7045), ZFP36L2 (678)
hsa-miR-181a-5p 231
AHNAK (79026), CD163 (9332), CDKN1B (1027), CEBPA (1050), CYP26B1 
(56603), DEPTOR (64798), EGR2 (1959), FPR3 (2359), MTURN (222166), 
SLA (6503), ZFP36L2 (678)
hsa-miR-92a-3p 221 CEBPA (1050), CRHBP (1393), EGR2 (1959), KLF2 (10365), LHFPL2 (10184), SGK1 (6446)
hsa-miR-146b-5p 161 CSF1R (1436), PPBP (5473), SDCBP (6386), TBC1D2 (55357)
hsa-miR-10a-5p 114 CLEC5A (23601), KBTBD11 (9920), MPL (4352)
hsa-miR-26a-5p 112 HOXA5 (3202), HOXA9 (3205)
hsa-miR-148a-3p 107 CDKN1B (1027), CLEC5A (23601), CTSL (1514), EMP1 (2012), FOSB (2354), GLIPR1 (11010), LIPA (3988), MPL (4352)
hsa-miR-486-5p 98 EMP1 (2012)
hsa-miR-28-3p 96 COL24A1 (255631)
hsa-miR-4792 92 ACP5 (54), RGCC (28984)
hsa-let-7a-5p 84 AGPAT9 (84803), CCL7 (6354), COL24A1 (255631), EVI2B (2124), GLRX (2745), HOXA9 (3205), MYCN (4613), OLR1 (4973), PLD3 (23646)
hsa-miR-3182 83 CYBB (1536), IGFBP7 (3490)
hsa-miR-423-3p 80 ZFP36L2 (678)
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CD33+: p-value < 0.05; CD38+: p-value < 0.01) 
(Figure 5B). No difference, instead, was found in 
UCB-CD34+ cells cultured in conditioned BM-MSC 
medium deprived of EVs compared to UCB-CD34+ 
cells cultured in medium alone (data not shown). To 
demonstrate that a decrease of cell differentiation 
is induced by BM-MSC EVs miRNAs we transfect 
together miR-27b-3p and miR-10a-5p (Figure 5C). 
After transfection we found significantly reduced the 
expression of MPL and ZFP36 (p-value < 0.01) (Figure 5D) 
and of the hematological marker CD38+ (p-value < 0.05) 
(Figure 5E) in transfected UCB-CD34+ cells vs control.
EVs treatment induces the expression of 
chemotactic factors from UCB-CD34+ cells
Through gene expression profile, we identified 103 
up-regulated genes. To validate their over-expression, we 
evaluated the mRNA expression levels of some of them, 
like IL1b, CSF2, CCL3, GATA2 and CXCR4. The transcript 
levels of all genes resulted significantly up-regulated 
(IL1b, CSF2 and CCL3: p-value < 0.001; GATA2 and 
CXCR4: p-value < 0.01) on UCB-CD34+ cells treated 
with EVs respect to the control (Figure 6A and 6B).
Furthermore, using IPA, we found that some of 
them (e.g., IL1b, CSF2, and CCL3) are under the control 
of genes targeted by miRNAs present in EVs (e.g., ZFP36/
miR-27b-3p and miR-423-5p, ABCA1/ miR-27b-3p) 
(Figure 6C). This analysis allowed to identify correlation 
pathways between up- and down-regulated genes driven 
by EVs miRNAs and having like a target function the 
chemotaxis of BM microenvironment cells.
Moreover, gene ontology analysis of up-regulated 
genes classified cellular movement and interaction 
from the most activated functions (Table 6). C-X-C 
chemokine receptor type 4 (CXCR4), for example, is a 
Table 2: Correlation of sequenced EVs piRNAs and down-regulated target genes in UCB-CD34+ 
treated with BM-MSC-EVs (p-value < 0.05, logFC = −0.7)
miRNA Regulated genes
Name readCount Symbol (Entrez Gene ID)
hsa_piR_020814_DQ598650 13 MPO(4353), SLC2A5 (6518), SLAMF8 (56833)
hsa_piR_002732_DQ573682 6 CYP1B1 (1545)
Table 3: Molecular and cellular functions of down-regulated genes in UCB-CD34+ treated with 
BM-MSC-EVs vs control (p-value < 0.05, logFC = −0.7)
Gene Ontology Bio Functions p-value
Molecular and Cellular Functions
Cell Death and Survival 3.89−10–4.07−03
Cell Morphology 2.20−09–4.07−03
Cellular Growth and Proliferation 2.20−09–3.85−04
Cellular Movement 4.42−08–4.15−03
Cellular Development 1.22−07–4.29−03
Table 4: Down-regulated miRNA target genes involved in cell death
Functions p-value Molecules
cell death 3.89E–10
CDKN1B,CEBPA,ALDH1A2,ANXA1,CAT,CCL7,CLEC5A,CSF1R,CTSL,CYBB,CYP1B1,
CYP26B1,DEPTOR,EGR2,EMP1,FCER2,FGR,FOSB,GLIPR1,GLRX,HOXA5,HOXA9,IGF
BP7,KLF2,LYZ,MPL,MYCN,OLR1,PPBP,S100A10,SGK1,TGFBI,ZFP36,ZFP36L2
apoptosis 7.43E–10
CDKN1B,CEBPA,ALDH1A2,ANXA1,CAT,CLEC5A,CSF1R,CTSL,CYBB,CYP1B1,CYP2
6B1,DEPTOR,EGR2,FCER2,FGR,FOSB,GLIPR1,GLRX,HOXA5,HOXA9,IGFBP7,KLF2,
MPL,MYCN,OLR1,S100A10,SGK1,TGFBI,ZFP36,ZFP36L2
necrosis 5.88E–08
CDKN1B,CEBPA,ALDH1A2,ANXA1,CAT,CSF1R,CYBB,CYP1B1,DEPTOR,EGR2,EMP
1,FCER2,FGR,FOSB,GLIPR1,GLRX,HOXA5,HOXA9,IGFBP7,KLF2,MPL,MYCN,OLR1
,PPBP,S100A10,SGK1,ZFP36
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physiologic receptor of CXCL12 expressed on HSC and 
essential for the engraftment of CD34+ cells in BM niche. 
CXCL12/CXCR4 interaction is a key component of HSC 
niche and their signal is necessary for maintaining HSCs 
quiescent [38, 39]. We evaluated CXCR4 expression 
observing its significant increase in UCB-CD34+ after 
EVs treatment respect to the control (p-value < 0.01) 
(Figure 6D and 6E). In light of these results, we 
investigated in vivo migration of UCB-CD34+ cells after 
EVs treatment. Treated cells demonstrated a significant 
increased engraftment (p-value < 0.01) of human 
cells in murine BM when compared to control cells 
(Figure 6F and 6G). Moreover, a significant decrease, at 
2 hours (p-value < 0.01) and 24 hours (p-value < 0.01) 
after injection, was observed between the number of 
peripheral blood human cells in mice engrafted with 
UCB-CD34+ treated versus control (Figure 6H–6I).
This analysis indicate that the EVs miRNAs 
induce, in UCB-CD34+ cells, the expression of different 
factors and receptors able to stimulate communication 
and movement of stem cells towards the niche 
microenvironment.
DISCUSSION
Cell communication represents a dynamic mechanism 
due to the release of factors able to influence cell fate, 
function and plasticity. BM-MSC are a heterogeneous 
population of cells [40] exerting their effect also by the 
EVs release. For instance, they induct reduction of pro-
inflammatory cytokines in graft versus host disease [32] 
Figure 4: Apoptosis analysis in UCB-CD34+ treated with BM-MSC-EVs vs control. (A) ANXA1, CEBPA and EGR2 mRNA 
relative expression was determined by qRT-PCR in UCB-CD34+ treated with 20 μg/ml of BM-MSC-EVs for 24 hours and their control. 
Each data samples were normalized to the endogenous reference GAPDH by use of the E-ΔΔCp. (B) Dot plot of one experiment shows a 
double PI/annexin V staining of UCB-CD34+ after 24 h of co-culture with or without BM-MSC-EVs (C) The mean percentage of apoptotic 
UCB-CD34+, after 24 h of co-culture with or without BM-MSC-EVs, was evaluated by PI/annexin V test. Results are expressed as a 
mean + SD of four independent experiments. (D) The percentage of caspase 3/7 positive UCB-CD34+, after 24 h of co-culture with or 
without BM-MSC-EVs, was evaluated by Caspase-3/7 Green flow cytometry assay. (E) miR-21-5p, miR-181a-5p and miR92a-3p relative 
expression was determined by qRT-PCR in UCB-CD34+ co-transfected with miRNAs mimic (miR-21-5p, miR-181a-5p and miR92a-3p) 
and scramble. Each data samples were normalized to the endogenous reference RNU44 by use of the E−ΔΔCp. (F) EGR2 and ANXA1 mRNA 
relative expression was determined by qRT-PCR in UCB-CD34+ co-transfected with miRNAs mimic and their scramble. Each data samples 
were normalized to the endogenous reference GAPDH by use of the E-ΔΔCp. (G) Representative image showing a double PI/annexin V 
staining of UCB-CD34+ after 24 h of miRNAs mimic or scramble transfection. (H) The percentage of apoptotic UCB-CD34+, after 24 h 
of miRNAs mimic or scramble transfection, was evaluated by PI/annexin V test. (I) The percentage of caspase 3/7 positive UCB-CD34+, after 
24 h of miRNAs mimic or scramble transfection, was evaluated by Caspase-3/7 Green flow cytometry assay. Results are expressed as a mean 
+ SD of three independent experiments. Statistically significant analyses are indicated by asterisks: *p < 0.05, **p < 0.01 and ***p < 0.001.
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and suppress angiogenesis in breast cancer [41]. EVs may 
express surface markers characteristic of originating cells 
[42, 43]. In fact, we found that BM-MSC derived EVs 
expressed several adhesion molecules of mesenchimal 
cells such as CD29, CD90, CD73, CD105, CD49d, 
CD146 and CD44. Moreover, several studies showed that 
EVs shuttle selected RNA proposing a new mechanism of 
genetic exchanging [6, 15, 44]. Sequencing BM-MSC-EVs 
small RNAs, we found 87 miRNAs and 5 piRNAs 
differentially expressed that are predicted to regulate cell 
differentiation and apoptosis. In particular, miR-21 is 
strongly involved in apoptosis pathways [45–47]; miR-10a 
plays a crucial role in megakaryocytic differentiation [48]. 
Among identified piRNAs, Hsa_piR_017723_DQ594464 
putatively targets FOS, a positive modulator of myeloid 
differentiation of hematopoietic progenitor [49]; 
hsa_piR_020814_DQ598650 targets SOX4, an apoptosis 
regulator in different human cancers [50, 51].
BM-MSC are a component of hematopoietic 
microenvironment [22] and are often used with other 
factors (SCF and IL6) to expand UCB-CD34+ cells 
in vitro [52, 53]. UCB-CD34+ cells are an alternative 
source to BM and mobilized peripheral blood HSC 
for hematopoietic cell transplantation, in particular 
for patients lacking a related or an adult unrelated 
HLA-matched donor. The advantages of using UCB-CD34+ 
cells respect to the other sources are a rapid availability, 
absence of risk for donor and decreased incidence of acute 
or chronic graft versus host disease [54, 55].
In this work, for the first time, communication 
between the BM-MSC-EVs and the UCB-CD34+ 
cells was studied, demonstrating that vesicles could be 
useful to improve re-population of BM niche. Our data 
indicated that BM-MSC-EVs miRNAs and piRNAs are 
able to influence the fate of UCB-CD34+ cells; in fact, 
gene expression profile of UCB-CD34+ cells treated 
with BM-MSC-EVs identified about 103 up-regulated 
and 100 down-regulated genes respect to control. The 
regulation of some of these genes, as IL6, CSF2, CCL3, 
CDKN1B, CEBPA, ANXA1, MPL, was confirmed by 
real time-PCR data, after both EVs treatment and EVs 
miRNAs overexpression. Interestingly, we found a 
correlation between BM-MSC-EVs miRNAs/piRNAs and 
down-regulated genes, indicating at least one target for 
each EVs miRNAs/piRNAs (e.g., CEBPA/miR-182, 
EGR2/miR-150 and miR-92, MPO/ hsa_piR_020814_
DQ598650). Analyzing these genes, we identified 
different suppressed biological functions, as cell death 
and differentiation. CCAAT enhancer binding protein-a 
(CEBPA), for example, is one of down-regulated genes 
that controls the balance between cell proliferation [56, 57] 
and differentiation during early hematopoietic and myeloid 
development [58, 59]. This gene is regulated by miR-182 
[60], one of the miRNAs found by sequencing in our 
BM-MSC EVs. Moreover, another down-regulated gene, 
Early Growth Response 2 (EGR2), also involved in 
apoptosis [61] and differentiation [62], is regulated by two 
different microRNAs, identified in our sequencing data, 
Table 5: Down-regulated miRNA target genes involved in cell development and differentiation
Functions p-value Molecules
development of blood cells 5.21E–05 ANXA1,CDKN1B,CEBPA,CSF1R,EGR2,HOXA5,HOXA9,KLF2,MPL,SLA
differentiation of leukocytes 5.48E–05 ANXA1,CDKN1B,CEBPA,CSF1R,EGR2,HOXA5,HOXA9,MYCN,SLA,ZFP36
differentiation of myeloid cells 1.73E–04 CDKN1B,CEBPA,CSF1R,HOXA5,HOXA9,ZFP36
differentiation of myeloid progenitor cells 3.12E–04 CDKN1B,CEBPA,HOXA9
differentiation of mononuclear leukocytes 3.39E–04 ANXA1,CDKN1B,CEBPA,CSF1R,EGR2,HOXA9,MYCN,SLA
development of leukocytes 6.80E–04 ANXA1,CDKN1B,CEBPA,CSF1R,EGR2,HOXA9,KLF2,SLA
differentiation of hematopoietic progenitor cells 7.95E–04 CDKN1B,CEBPA,CSF1R,HOXA5,HOXA9
differentiation of cells 8.91E–04
ALDH1A2,ANXA1,CAT,CDKN1B,CEBPA,CSF1R,CY
P26B1,EGR2,HOXA5,HOXA9,IGFBP7,MPL,MYCN,R
GS2,SLA,ZFP36
development of hematopoietic progenitor cells 1.99E–03 CDKN1B,EGR2,HOXA5,MPL
development of lymphocytes 2.17E–03 ANXA1,CDKN1B,CEBPA,EGR2,HOXA9,KLF2,SLA
development of bone marrow cells 2.22E–03 CEBPA,HOXA5,MPL
differentiation of granulocytes 3.00E–03  CDKN1B,CEBPA,HOXA9
differentiation of monocytes 3.16E–03 CEBPA,CSF1R,HOXA9
differentiation of neutrophils 4.29E–03 CEBPA,HOXA9
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miR-150 [63] and miR-92 [64]. MPO, instead, synthesized 
during myeloid differentiation [65, 66], is putatively 
regulated by our hsa_piR_020814_DQ598650.
All these data support a direct down-regulation 
by BM-MSC-EVs miRNAs/piRNAs of target genes in 
UCB-CD34+ cells after co-culture.
Induction of cell viability and inhibition of cellular 
maturation of UCB-CD34+ cells after EVs treatment 
respect to control were also assessed by functional tests. 
In particular, we observed a decreased caspase dependent 
apoptosis and a decreased expression of hematopoietic 
differentiation markers. 
Moreover, we demonstrated that EVs effect is due 
to BM-MSC-derived EVs miRNAs. In fact, UCB-CD34+ 
cells, after overexpression of miR-21-5p, miR-181a-5p and 
miR92a-3p showed a significant decrease of apoptosis pathway 
and of caspase 3/7 activity. By contrast, over-expression of 
miR-27b-3p and miR-10a-5p showed a reduction of CD38 
expression, i.e. a phenotypic pattern typical of undifferentiated 
stem cells.
Finally, gene expression profile identified 103 
up-regulated genes (e.g., IL6, CSF2, CCL3) that, by IPA, 
were found under the control of miRNA targeted genes 
(e.g., ZFP36/miR-27b-3p). 
Of interest, most of these genes codify for 
chemokines and cytokines (and their receptors) involved 
in the chemotaxis process of different BM cell types, 
thus suggesting their potential role in the reconstitution 
of marrow microenvironment which is fundamental for 
transplant engraftment. Cytokines modulate and sustain 
hematopoiesis acting on stem/progenitor cells and accessory 
cells, such as stromal cells, that can further regulate 
proliferation, differentiation, survival, migration and 
homing of these cells. Cytokine activity is mediated through 
specific receptors that transmit important signals for cell 
fate [67, 68]. CXCR4, for example, was found up-regulated 
in UCB after EVs treatment suggesting the induction of 
homing and quiescence in presence of CXCL12 [38, 39]. 
We demonstrated that over-expression of cytokines 
and chemokines after EVs treatment induces an increased 
Figure 5: Cellular differentiation in UCB-CD34+ treated with BM-MSC-EVs vs control. (A) MPL and ZFP36 mRNA relative 
expression was determined by qRT-PCR in UCB-CD34+ treated with 20 μg/ml of BM-MSC-EVs for 24 hours and their control. Each data 
samples were normalized to the endogenous reference GAPDH by use of the E-ΔΔCp. (B) The percentage of CD38, CD33 and CD19 positive 
UCB-CD34+, after 24 h of co-culture with or without BM-MSC-EVs, was evaluated by FACS analysis. (C) miR-27b-3p and miR-10a-5p 
relative expression was determined by qRT-PCR in UCB-CD34+ co-transfected with miRNAs mimic (miR-27b-3p and miR-10a-5p) 
and scramble. Each data samples were normalized to the endogenous reference RNU44 by use of the E-ΔΔCp. (D) MPL mRNA relative 
expression was determined by qRT-PCR in UCB-CD34+ co-transfected with miRNAs mimic and their scramble. Each data samples were 
normalized to the endogenous reference GAPDH by use of the E-ΔΔCp. (E) The percentage of CD38 positive UCB-CD34+, after transfection 
of miRNAs mimic or scramble, was evaluated by FACS analysis. Results are expressed as a mean + SD of three independent experiments. 
Statistically significant analyses are indicated by asterisks: *p < 0.05, **p < 0.01 and ***p < 0.001.
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migration of UCB from peripheral blood to BM in 
NSG mice. Of interest, in vivo experiments showed 
an improvement of UCB-CD34+ migration potential 
due to EVs treatment. In fact, after only 2 hours from 
transplantation we found halved numbers of CD34+ in 
peripheral blood. Our data indicated that BM-MSC-EVs 
could be helpful in BM microenvironment reconstitution 
even though the maintenance of HSCs pool over time after 
transplant depends on balance between self-renewal and 
differentiation.
In conclusion, BM-MSC-EVs combined with HSC 
may contribute to the hematopoietic microenvironment 
Figure 6: Expression of chemotactic factors in UCB-CD34+ treated with BM-MSC-EVs vs control. (A–B) IL1b, CSF2, 
CCL3, GATA2 and CXCR4 mRNA relative expression was determined by qRT-PCR in UCB-CD34+ treated with 20 μg/ml of BM-MSC-EVs 
for 24 hours and their control. Each data samples were normalized to the endogenous reference GAPDH by use of the E-ΔΔCp. 
(C) In-silico regulator effect analysis of EVs sequenced miRNAs and UCB-CD34+ gene expression profile treated with vesicles. Chemotaxis 
of cells is supported by the up-regulation of selected genes (IL1B, CCL3L1/3, PTGS2, IL6, IL23A, CFS2) that are under control of 
down-regulated genes (ZFP36, ABCA1, ANXA1). All these genes are differentially expressed in GEP analysis. Down-regulated genes are 
in-silico linked (by TargetScan) to most representative miRNA sequenced by EVs. (D) Representative image showing a double anti-CD34/
anti-CXCR4 staining of UCB-CD34+ after 24 h of co-culture with or without BM-MSC-EVs. (E) The percentage of CXCR4 positive 
UCB-CD34+, after 24 h of co-culture with or without BM-MSC-EVs, was evaluated by FACS analysis. (F) Number of human CD34 
positive cells per 1 × 106 acquired cells in murine BM after 24 hours of transplantation. (G) Representative image of F. (H) Number of 
human CD34 positive cells per µl of murine PB acquired, after 2 and 24 hours of transplantation. (I) Representative image of H. The Results 
are expressed as a mean + SD of three independent experiments. Statistically significant analyses are indicated by asterisks: *p < 0.05, 
**p < 0.01 and ***p < 0.001.
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reconstitution representing a new therapeutic option 
(e.g., transplantation, gene therapy) for different diseases 
as hematological cancers.
MATERIALS AND METHODS
Cell culture
Cord blood unit were provided by Cord Blood Bank 
of Research Institute “Casa Sollievo della Sofferenza”, 
San Giovanni Rotondo. Mononuclear cells were obtained 
by Ficoll-Paque gradient centrifugation. UCB-CD34+ 
cells were isolated from mononuclear cells by CD34 
Microbead Kit (Miltenyi Biotec, Auburn, CA). The 
purity of isolated CD34+ cells routinely ranged between 
90–95%. Primary BM-MSC were isolated from bone 
marrow aspirate of a healthy subject provided by Prof. 
Francesco Frassoni’s laboratory (Giannina Gaslini 
Institute, Genova). BM-MSC were cultured in DMEM 
(Gibco, Life technologies, Carlsbad, CA, USA) 
supplemented with 10% of fetal bovine serum (FBS) 
(Gibco), 1% of penicillin-streptomycin and 2 mM of 
L-glutamine (Gibco). Cells were grown at 37°C in 5% 
CO2. BM-MSC were seeded in 175 cm
2 tissue culture 
flasks at a density of 10,000 cells/cm2 and used within 
the sixth passage of culture for experiments [42]. At each 
passage, cells were counted, analyzed by cytometric 
analysis and immunofluorescence to confirm their 
phenotype. Cells were characterized by FACS analysis for 
the expression of mesenchymal stem cell markers [69]. 
BM-MSC were able to undergo osteogenic, adipogenic 
and condrogenic differentiation when cultured in 
appropriate differentiative media [70].
FACS analysis of BM-MSC cells
To confirm their phenotype, BM-MSC were analyzed by 
FACS Calibur cytometer using CellQuest software. Cells were 
labeled with following fluorochrome-conjugated monoclonal 
antibodies and their specific isotypic control: allophycocyanin 
(APC)-anti CD29 (IgG1k, Clone MAR4; BD Pharmingen); 
peridinin chlorophyll (PerCP)-anti CD90 (IgG1k, Clone 5E10; 
BD Pharmingen); phycoerythrin (PE)-anti CD73 (IgG1k, 
Clone AD-2; BD Pharmingen); PE-anti CD105 (IgG3, Clone 
1G2, Beckman Coulter); PerCP-anti CD45 (IgG1k, Clone 
2D1, BD Pharmingen); PE-anti CD49d (IgG1k, Clone 9F10; 
BD Pharmingen); PE-anti CD146 (IgG1k, Clone P1H12, BD 
Pharmingen); APC-anti CD44 (IgG2b k, Clone G44-26, BD 
Pharmingen); fluorescein isothiocyanate (FITC)-anti HLA-
DR (IgG2a k, Clone L243, BD Pharmingen); APC-anti CD14 
(IgG2b k, Clone MØP9, BD Pharmingen); PE-anti CD144 
(IgG2b, Clone 123423, R & D System); FITC-anti CD31 
(IgG1 k, Clone WM59, BD Pharmingen).
Isolation and characterization of EVs
EVs were obtained from supernatants of 
BM-MSC cultured in DMEM supplemented with 10% 
FBS deprived of EVs, 1% of penicillin-streptomycin 
and 2 mM of L-glutamine. FBS was deprived of EVs by 
ultracentrifugation (Beckman Coulter, Miami, FL, USA) 
at 100,000 g overnight at 4°C before use. 
The method used for isolation of cell derived 
vesicles was previously described by Théry et al. [71]. In 
short, BM-MSC and media were centrifuged at 300 × g 
for 10 min at 4°C after 48 h of culture. Supernatant 
was collected and centrifuged again at 2,000 × g for 20 
min at 4°C; subsequently it was harvested and vacuum 
ultracentrifuged at 10,000 × g for 30 min at 4°C to 
remove residual cell debris. Supernatant was collected 
and ultracentrifuged at 100,000 × g for 70 min at 4°C 
with vacuum. The resulting supernatant was discarded; 
pellets from multiple tubes were resuspended in 1 ml of 
PBS, pooled into a single tube and ultracentrifuged at 
100,000 × g as described previously. Pellets of vesicles 
were resuspended in filtered PBS with HEPES 25 mM and 
the protein content was measured by the Bradford assay 
(BioRad, Hercules, CA, USA). EVs were stored frozen at 
−80°C in DMSO 0.1%.
The size of EVs was determined by cytometric 
analysis. The system was calibrate using standard 
microbeads with a diameter of 0.3–0.9–3 μm (Megamix, 
BD) and prefiltered (0.22 μm) PBS was used to define EVs 
gate. To characterize EVs, samples were labeled using 
PE-CD105, PE-CD73, PE-CD146, PE-CD81 (IgG1k, 
Clone JS-81, BD Pharmingen), PE-CD49d, PerCP-CD45, 
PerCP-CD90, APC-CD29, APC-CD44 and their specific 
isotypic control.
Table 6: Molecular and cellular functions of up-regulated genes in UCB-CD34+ treated with 
BM-MSC-EVs vs control
Gene Ontology Bio Functions p-value
Molecular and Cellular Functions
 Cellular Movement 2.25−39–2.42−07
 Cell-To-Cell Signaling and Interaction 8.73−30–2.28−07
 Cellular Function and Maintenance 1.82−28–3.37−08
 Cellular Growth and Proliferation 2.31−27–2.51−07
 Cellular Development 6.09−27–1.22−07
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Transmission electron microscopy (TEM)
EVs from BM-MSC were suspended in PBS and 
loaded onto 200 mesh nickel formvar carbon coated grids 
(Assing, Roma). EVs were fixed in 1.25% glutaraldehyde 
and 1% paraformaldehyde in 0.1 M Sorensen’s phosphate 
buffer for 15 min and then washed in 0.1 M Sorensen’s 
phosphate buffer for 4 times. After air dry, EVs were 
examined by transmission electron microscopy PHILIPS 
CM12 TEM.
Co-culture of UCB-CD34+ and EVs
Six million of UCB-CD34+ were plated a 6-well 
plate and cultured using three different conditions: a) 1.5 ml 
of DMEM supplemented with 5% FBS deprived of EVs, 
1% penicillin-streptomycin and 2 mM L-glutamine; 
 b) 1.5 ml of DMEM supplemented with 5% FBS deprived 
of EVs, 1% penicillin-streptomycin, 2 mM L-glutamine 
and 20 μg/ml of BM-MSC-EVs [15, 72]; c) conditioned 
medium of BM-MSC deprived of BM-MSC-EVs. After 
24 hours of co-culture UCB-CD34+ cells were collected.
Apoptosis assay
1 × 10^5 UCB-CD34+ treated or not with EVs were 
washed twice with cold PBS and then resuspended in 
100 µl of 1X Binding Buffer (BD Pharmagen, Italy) with 
5 µl of FITC Annexin V (BD Pharmagen, Italy) and 5 µl 
propidium iodide (PI) (BD Pharmagen, Italy) for 15 min 
at room temperature in the dark. After incubation 400 µl of 
1X Binding Buffer were added to each tube and analyzed by 
FACSCalibur flow cytometry (BD Biosciences).
Caspase 3/7 activity assay
Caspase 3/7 activity was measured with the 
CellEvent™ caspase 3/7 Green Detection Reagent 
(Life technologies). On cleavage by activated caspase 3/7, 
the probe becomes fluorescent and free to bind to DNA. 
Cells were incubated with 1 μM CellEvent™ caspase 3/7 
green detection reagent in complete medium for 30 min 
at 37°C in the dark. Stained cells were observed by flow 
cytometry.
RNA extraction
RNA was extracted using Trizol reagent 
(Life Technologies) according to the manufacturer’s 
instructions. Total RNA was quantified with a NanoDrop 
2000c spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA) and its quality was assessed by capillary 
electrophoresis on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Inc, Santa Clara, CA) using RNA 6000 Nano 
or RNA Pico Chip Assay Kit (Agilent). The presence of 
small RNAs in EVs samples was verified using Small RNA 
Chip (Agilent). For RNA isolated from UCB-CD34 + cells, 
only a RNA integrity number (RIN) > 8 was used. Since 
the intact 18S and 28S rRNA were scarcely detectable in 
EVs, the RIN was not a constrain for these samples.
Microarray data analysis
For each sample, 300 ng of total RNA was 
reverse transcribed and used for synthesis of cDNA and 
biotinylated cRNA according to the Illumina TotalPrep 
RNA amplification kit protocol (Ambion, Austin, TX; 
category number IL1791). Hybridization of 750 ng 
of cRNA on Illumina HumanHT12 v4.0 Expression 
BeadChip array (Illumina Inc., San Diego, CA, USA), 
staining and scanning were performed according to the 
standard protocol supplied by Illumina. All preparation 
was performed in triplicate for each sample. BeadChip 
was dried and scanned with an Illumina HiScanSQ system 
(Illumina Inc.).
The intensity files were loaded into the Illumina 
Genome Studio software for quality control and gene 
expression analysis. Quantile normalization algorithm 
was applied on the data set to correct systematic errors, 
values below a detection score of 0.05 were filtered out 
and missing values were imputed. Differently expressed 
genes (DEGs) were selected with differential score 
(DiffScore) cutoff set at ± 30 (p < 0.001) and genes with 
log2fold difference ≤ −0.7 or ≥ 0.7 (more than 1.5-fold 
change) were further analyzed (Supplementary Table 2). 
Microarray data were submitted to Array Express under 
accession number E-MTAB-3576. DEGs list (composed 
by 230 genes, 103 up-regulated and 100 down-regulated) 
was used to evaluate the functional behavior in terms of 
Biological Processes performing an enrichment analysis 
with Ingenuity Pathway Analysis (IPA) (Ingenuity 
Systems; Mountain View, CA, USA).
Small RNA sequencing
For sequencing, 1 μg of total RNA/EVs pool was 
used for library preparation with Illumina TruSeq small 
RNA sample preparation Kit. The library (10 pM) was 
sequenced on HiSeq1000 (Illumina) for 50 cycles. Small 
RNA sequencing data were analyzed using iMir [33] and 
mature miRNA list obtained with miRanalyzer [73] was 
used to characterize EVs small RNA content. Mature 
microRNAs with a readCount less than 5 were removed. 
Final mature microRNAs readCount list was subdivided in 
quartiles on readCount number (Supplementary Table 1) 
and only the 1st was used in the integrated analysis with 
gene expression profiling array (Table 1). 
The sequencing data were preprocessed for piRNAs 
by Flexbar v.2.5 [74] and then analyzed by piPipes 
smallRNA v. 1.0.2. [34] (piRNA length range: 23–36 nt). 
PiRNAs with a readCount less than 5 were removed 
(Figure 2F).
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The most representative sequences were classified 
in piRNABank (Institute of Bioinformatics and Applied 
Biotechnology, Bangalore, India) [75] and putative piRNA 
target RNAs were identified using miRanda v.3.3a [35] 
with alignment score (sc; ≥ 170) and energy threshold 
(en; ≤ −20.0 kcal/mol) by complementary sequence 
between each piRNA and the 5′-UTRs, CDSs or 3′-UTRs 
of all known human RNAs (Ensembl gene annotation). 
The piRNA gene list was crossed with gene expression 
profile identifying 18 common piRNA target genes used 
then for integrated analysis with IPA (p-value < 0.05 and 
logFC ≤ −0.4). 
Raw small RNA sequencing data are available in NCBI 
Gene Expression Omnibus (GEO) database (http://www.
ncbi.nlm.nih.gov/gds/) with Accession Number SRP058423.
Quantitative real-time PCR 
Quantitative real-time PCRs (qRT-PCRs) were 
performed with the TaqMan PCR Kit (Applied Biosystems, 
Foster City, CA) according to manufacturer’s instructions, 
followed by detection with the Light Cycler 480 
(Roche, Australia). The appropriate TaqMan probes for 
mRNA and microRNA quantification were purchased 
from Applied Biosystems. All reactions were performed 
in triplicate. Simultaneous quantification of GAPDH 
mRNAs and RNU44 were used as a reference for mRNA 
and microRNA TaqMan assay data normalization. The 
comparative cycle threshold (Ct) method for relative 
quantification of gene expression (User Bulletin #2; 
Applied Biosystems) was used to determine mRNA 
expression levels. 
UCB-CD34+ cell transfection 
UCB-CD34+ were transfected with 60 nM of miRNA 
precursor molecules (miR-27b-3p mimic, miR-10a-5p mimic, 
miR-21-5p mimic, miR-181a-5p mimic and miR92a-3p mimic) 
(Life Technologies) or negative control (Life Technologies) 
using Lipofectamine 2000 (Life Technologies), according to 
the manifacturer’s instructions. After 24 hours of transfection 
cells were collected and used for cytometric analysis and for 
RNA isolation.
Mice
For in vivo studies, 8-week old NOD-SCID-Il2rg-/- 
(NSG) mice were purchased by Jackson Laboratory. The 
experimental protocol was approved by the Institutional 
Animal Facility of Biogem Research Institute. 2 × 105 
UCB-CD34+ cells treated or not with EVs for 24 hours 
were injected by tail vein into every mouse. After 2 and 
24 hours from injection, sub-mandibular blood was 
collected. For analysis of engraftment experimental mice 
were sacrificed 24 hours post-transplantation and the BM 
was obtained from femur and tibia. To determine the 
number of CD34+/µl, blood was transferred in truCOUNT 
tube, incubated with specific anti-human CD45 
FITC/CD34 PE, lysed with 1X ammonium chloride lysing 
solution according to the manufacturer’s procedures 
(BD Stem Cell Enumeration Kit) and acquired by FACS 
CANTO II. Analysis was performed with FACS DIVA 
software. CD34 + number was calculated with the formula 
CD34+/µl = CD34 + acquired/ trucount events x total bead 
count/100 µl of blood.
Cells from BM were labeled with specific 
anti-human CD45 FITC/CD34 PE and resuspended 
in PBS. For each sample 5 × 106 events were acquired. 
CD34+ rate was expressed as number of positive cells/
million of acquired events.
Statistical analysis
Student’s t-test was used to determine significance 
(indicated as p-value). All error bars represent the standard 
deviation (SD) of the mean.
IPA and integrated analysis
Gene interaction networks, bio functions and 
pathway analysis were generated by IPA, which assists 
with microarray data interpretation via grouping 
differentially expressed genes (DEGs) into known 
functions, pathways, and networks primarily based on 
human and rodent studies. The DEGs were organized 
in Gene Ontology Bio Functions and Regulatory Effect 
Networks available from the Ingenuity database. The 
significance was set at a p-value of 0.05.
IPA pathway explorer and TargetScan 
(http://www.targetscan.org/) were used to find a link between 
down-regulated genes in array experiment and 1st quartile 
of miRNA sequenced by EVs, looking for putative causal 
effect in EVs treatment of UCB-CD34+. 
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